Manara - Qatar Research Repository
Browse
10.3389_fimmu.2022.1119363.pdf (2.05 MB)

Editorial: Engineered immune cells in cancer immunotherapy (EICCI)

Download (2.05 MB)
journal contribution
submitted on 2024-04-03, 07:18 and posted on 2024-04-03, 07:19 authored by Francisco Martin, Axel Schambach, Cristina Maccalli

Adoptive Cell Therapy (ACT) to treat cancer represents a rapidly evolving field. New approaches for the genetic engineering of immune effector cells with either a T cell receptor (TCR) or a chimeric antigen receptor (CAR) (Figure 1 Panels A and B, respectively) have led to the increase of the clinical efficacy, the reduction or better control of toxicities and the expansion of the indications of these therapies. The Research Topic “Engineered Immune Cells in Cancer Immunotherapy (EICCI)” represents the venue for collecting studies, new evidence, advances in the technologies and the greatest knowledge for the translational application on the topic of cellular therapy for cancer. The great success of this Research Topic with the publication of total 46 articles, including 18 original articles, 20 reviews, 5 mini reviews, 2 case reports and 1 methodology manuscript, and the contributions of 360 authors, testify to the huge interest of the scientific community in this field and the numerous advancements.

Other Information

Published in: Frontiers in Immunology
License: https://creativecommons.org/licenses/by/4.0/
See article on publisher's website: https://dx.doi.org/10.3389/fimmu.2022.1119363

History

Language

  • English

Publisher

Frontiers

Publication Year

  • 2022

License statement

This Item is licensed under the Creative Commons Attribution 4.0 International License.

Institution affiliated with

  • Sidra Medicine
  • Hamad Bin Khalifa University
  • College of Health and Life Sciences - HBKU

Usage metrics

    College of Health and Life Sciences - HBKU

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC